Movement Disorders Clinical Practice最新文献

{"title":"The Quality in Quality of Life in Parkinson's Disease: A Qualitative Meta-Synthesis.","authors":"Marlena van Munster, Anna J Pedrosa, Carolin Künkler, David J Pedrosa","doi":"10.1002/mdc3.14063","DOIUrl":"10.1002/mdc3.14063","url":null,"abstract":"<p><strong>Background: </strong>Quality of life (QoL) is known to be impaired in people with Parkinson's disease (PwPD). Not surprisingly, a considerable effort of health interventions is aimed at maintaining or improving QoL. Yet, little is known about its determinants from a PwPD perspective to inform person-centered health care interventions.</p><p><strong>Objectives: </strong>This systematic review aims to overcome this information gap by synthesizing existing evidence on factors associated with PwPD' self-perceived QoL.</p><p><strong>Methods: </strong>We searched six electronic databases (MEDLINE, EMBASE, PsycINFO, CINAHL, Web of Science, Cochrane Library) from inception to January 2022 for eligible qualitative studies of QoL in PwPD, supplemented by citation tracking and hand searching. Study quality was assessed using the QualSyst tool. In order to characterize the determinants of QoL in PwPD, we conducted a qualitative meta-synthesis.</p><p><strong>Results: </strong>Our analysis revealed a wide range of facilitators and barriers to QoL relating to seven overarching themes: Illness experience, health care, everyday life, social life, identity, spirituality/religion, and environment.</p><p><strong>Conclusions: </strong>Our systematic review reinforces the impact of symptom experience on PwPD's QoL. However, it also highlights the need to consider the non-physical dimensions of PD when assessing patients' QoL. It is therefore essential that health care professionals acknowledge the psychological, social and spiritual repercussions of PD and endeavor to respond to these concerns through a comprehensive and patient-centered strategy. Further research is needed to gain a deeper understanding of these facets of PD and to formulate successful interventions aimed at improving the QoL of PwPD.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Neurofilament Light and Clinical Biomarkers for Disease Staging in Huntington's Disease.","authors":"Beatrice Heim, Elias Mandler, Arabella Buchmann, Anna Grossauer, Marina Peball, Dora Valent, Federico Carbone, Katarína Schwarzová, Atbin Djamshidian, Philipp Mahlknecht, Michael Khalil, Florian Krismer, Klaus Seppi","doi":"10.1002/mdc3.13993","DOIUrl":"10.1002/mdc3.13993","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140294014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study.","authors":"Diego Santos-García, Teresa de Deus, Carlos Cores, Maria J Feal Painceiras, María C Íñiguez Alvarado, Lucía B Samaniego, Antón López Maside, Silvia Jesús, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Ines Legarda, Jorge Hernández-Vara, Iria Cabo López, Lydia López Manzanares, Isabel González-Aramburu, Asunción Ávila, Víctor Gómez-Mayordomo, Víctor Nogueira, Julio Dotor García-Soto, Carmen Borrué-Fernández, Berta Solano, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Zebenzui Mendoza, Isabel Pareés, Pilar Sánchez Alonso, Maria G Alonso Losada, Nuria López-Ariztegui, Itziar Gastón, Jaime Kulisevsky, Manuel Seijo, Caridad Valero, Ruben Alonso Redondo, Maria Teresa Buongiorno, Carlos Ordás, Manuel Menéndez-González, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir","doi":"10.1002/mdc3.14056","DOIUrl":"10.1002/mdc3.14056","url":null,"abstract":"<p><strong>Background: </strong>Levodopa-induced dyskinesias (LID) are frequent in Parkinson's disease (PD).</p><p><strong>Objective: </strong>To analyze the change in the frequency of LID over time, identify LID related factors, and characterize how LID impact on patients' quality of life (QoL).</p><p><strong>Patients and methods: </strong>PD patients from the 5-year follow-up COPPADIS cohort were included. LID were defined as a non-zero score in the item \"Time spent with dyskinesia\" of the Unified Parkinson's Disease Rating Scale-part IV (UPDRS-IV). The UPDRS-IV was applied at baseline (V0) and annually for 5 years. The 39-item Parkinson's disease Questionnaire Summary Index (PQ-39SI) was used to asses QoL.</p><p><strong>Results: </strong>The frequency of LID at V0 in 672 PD patients (62.4 ± 8.9 years old; 60.1% males) with a mean disease duration of 5.5 ± 4.3 years was 18.9% (127/672) and increased progressively to 42.6% (185/434) at 5-year follow-up (V5). The frequency of disabling LID, painful LID, and morning dystonia increased from 6.9%, 3.3%, and 10.6% at V0 to 17.3%, 5.5%, and 24% at V5, respectively. Significant independent factors associated with LID (P < 0.05) were a longer disease duration and time under levodopa treatment, a higher dose of levodopa, a lower weight and dose of dopamine agonist, pain severity and the presence of motor fluctuations. LID at V0 (β = 0.073; P = 0.027; R² = 0.62) and to develop disabling LID at V5 (β = 0.088; P = 0.009; R² = 0.73) were independently associated with a higher score on the PDQ-39SI.</p><p><strong>Conclusion: </strong>LID are frequent in PD patients. A higher dose of levodopa and lower weight were factors associated to LID. LID significantly impact QoL.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140922888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Medication Profiles in Parkinson's Disease under Subthalamic Deep Brain Stimulation: A Controlled Study.","authors":"Christoph Theyer, Vincent Beliveau, Florian Krismer, Marina Peball, Katherina Mair, Beatrice Heim, Atbin Djamshidian, Stefan Kiechl, Wilhelm Eisner, Sabine Eschlböck, Gregor K Wenning, Peter Willeit, Klaus Seppi, Werner Poewe, Philipp Mahlknecht","doi":"10.1002/mdc3.14065","DOIUrl":"10.1002/mdc3.14065","url":null,"abstract":"<p><strong>Background: </strong>Subthalamic deep brain stimulation (STN-DBS) reduces antiparkinsonian medications in Parkinson's disease (PD) compared with the preoperative state. Longitudinal and comparative studies on this effect are lacking.</p><p><strong>Objective: </strong>To compare longitudinal trajectories of antiparkinsonian medication in STN-DBS treated patients to non-surgically treated control patients.</p><p><strong>Methods: </strong>We collected retrospective information on antiparkinsonian medication from PD patients that underwent subthalamic DBS between 1999 and 2010 and control PD patients similar in age at onset and baseline, sex-distribution, and comorbidities.</p><p><strong>Results: </strong>In 74 DBS patients levodopa-equivalent daily dose (LEDD) were reduced by 33.9-56.0% in relation to the preoperative baseline over the 14-year observational period. In 61 control patients LEDDs increased over approximately 10 years, causing a significant divergence between groups. The largest difference amongst single drug-classes was observed for dopamine agonists.</p><p><strong>Conclusion: </strong>In PD patients, chronic STN-DBS was associated with a lower LEDD compared with control patients over 14 years.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Conversations about Parkinson's Dementia.","authors":"Ivelina Dobreva, Joanne Thomas, Anne Marr, Ruairiadh O'Connell, Moïse Roche, Naomi Hannaway, Charlotte Dore, Sian Rose, Ken Liu, Rohan Bhome, Sion Baldwin-Jones, Janet Roberts, Neil Archibald, Duncan Alston, Khaled Amar, Emma Edwards, Jennifer A Foley, Victoria J Haunton, Emily J Henderson, Ashwani Jha, Fiona Lindop, Cathy Magee, Luke Massey, Eladia Ruiz-Mendoza, Biju Mohamed, Katherine Patterson, Bhanu Ramaswamy, Anette Schrag, Monty Silverdale, Aida Suárez-González, Indu Subramanian, Tom Foltynie, Caroline H Williams-Gray, Alison J Yarnall, Camille Carroll, Claire Bale, Cassandra Hugill, Rimona S Weil","doi":"10.1002/mdc3.14054","DOIUrl":"10.1002/mdc3.14054","url":null,"abstract":"<p><strong>Background: </strong>People with Parkinson's disease (PD) have an increased risk of dementia, yet patients and clinicians frequently avoid talking about it due to associated stigma, and the perception that \"nothing can be done about it\". However, open conversations about PD dementia may allow people with the condition to access treatment and support, and may increase participation in research aimed at understanding PD dementia.</p><p><strong>Objectives: </strong>To co-produce information resources for patients and healthcare professionals to improve conversations about PD dementia.</p><p><strong>Methods: </strong>We worked with people with PD, engagement experts, artists, and a PD charity to open up these conversations. 34 participants (16 PD; 6 PD dementia; 1 Parkinsonism, 11 caregivers) attended creative workshops to examine fears about PD dementia and develop information resources. 25 PD experts contributed to the resources.</p><p><strong>Results: </strong>While most people with PD (70%) and caregivers (81%) shared worries about cognitive changes prior to the workshops, only 38% and 30%, respectively, had raised these concerns with a healthcare professional. 91% of people with PD and 73% of caregivers agreed that PD clinicians should ask about cognitive changes routinely through direct questions and perform cognitive tests at clinic appointments. We used insights from the creative workshops, and input from a network of PD experts to co-develop two open-access resources: one for people with PD and their families, and one for healthcare professionals.</p><p><strong>Conclusion: </strong>Using artistic and creative workshops, co-learning and striving for diverse voices, we co-produced relevant resources for a wider audience to improve conversations about PD dementia.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140857222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa.","authors":"K Ray Chaudhuri, Maurizio F Facheris, Bruno Bergmans, Filip Bergquist, Susan R Criswell, Jia Jia, Pavnit Kukreja, Yohei Mukai, Amy M Spiegel, Resmi Gupta, Lars Bergmann, Rajesh Pahwa","doi":"10.1002/mdc3.14018","DOIUrl":"10.1002/mdc3.14018","url":null,"abstract":"<p><strong>Background: </strong>Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs.</p><p><strong>Objectives: </strong>Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167).</p><p><strong>Methods: </strong>Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and \"Off\"/\"On\" times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score.</p><p><strong>Results: </strong>Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved \"Off\" time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, \"Off\" time, QoL, and m-EDL.</p><p><strong>Conclusions: </strong>Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and \"Off\" time.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical Presentations of Huntington Disease-like 2 in South African Individuals.","authors":"Heena Narotam-Jeena, Mark Guttman, Ludo van Hillegondsberg, Riaan van Coller, Amanda Krause, Jonathan Carr","doi":"10.1002/mdc3.14052","DOIUrl":"10.1002/mdc3.14052","url":null,"abstract":"<p><strong>Background: </strong>Huntington disease-like 2 (HDL2) is a neurodegenerative disorder, affecting only individuals of African ancestry. Full penetrance occurs in individuals with 40 repeats or more.</p><p><strong>Objective: </strong>To describe the phenotypic variability of HDL2 in a group of mixed ancestry individuals from South Africa.</p><p><strong>Methods: </strong>Eight patients were assessed with analysis of repeat size and magnetic resonance brain imaging. We applied the Unified Huntington's Disease Rating Scale (UHDRS), but in deceased patients (4), this was estimated from video material.</p><p><strong>Results: </strong>Cognitive domains were more severely affected than motor; UHDRS motor scores were notable for bradykinesia, and to a slightly lesser extent, for rigidity and dystonia; a single patient had marked chorea. Repeat lengths ranged from 45 to 63 (median, 52).</p><p><strong>Conclusion: </strong>This South African group of mixed ancestry HDL2 individuals presented with severe cognitive and behavioral impairments, with lesser degrees or absence of chorea. This presentation is possibly related to large repeat sizes.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140899092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Memoriam Gregor K. Wenning (1964-2024).","authors":"Werner Poewe, Horacio Kaufmann, Niall Quinn","doi":"10.1002/mdc3.14134","DOIUrl":"10.1002/mdc3.14134","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141498524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Movement Disorders in Patients with Subacute Sclerosing Panencephalitis: A Systematic Review.","authors":"Divyani Garg, Sahil Patel, Charulata S Sankhla, Vikram V Holla, Vijayashankar Paramanandam, Prashanth L Kukkle, Sanjay Pandey, Susanne A Schneider, Pramod K Pal","doi":"10.1002/mdc3.14062","DOIUrl":"10.1002/mdc3.14062","url":null,"abstract":"<p><strong>Background: </strong>Subacute sclerosing panencephalitis (SSPE) is a complication of measles, occurring after a latency of 4-10 years. It continues to occur in developing countries although resurgence is being reported from developed countries. Characteristic features include progressive neuropsychiatric issues, myoclonus, seizures, movement disorders and visual impairment. Electroencephalography (EEG) typically shows periodic generalized discharges, and elevated CSF anti-measles antibodies are diagnostic. Movement disorders are being increasingly recognized as part of the clinical spectrum, and range from hyperkinetic (chorea, dystonia, tremor, tics) to hypokinetic (parkinsonism) disorders and ataxia.</p><p><strong>Objectives: </strong>This article aims to comprehensively review the spectrum of movement disorders associated with SSPE.</p><p><strong>Methods: </strong>A literature search was conducted in PubMed and EMBASE databases in December 2023 and articles were identified for review.</p><p><strong>Results: </strong>Movement disorders reported in SSPE included hyperkinetic (chorea, dystonia, tremor and tics), hypokinetic (parkinsonism), ataxia and extraocular movement disorders. Myoclonus, a core clinical feature, was the most frequent \"abnormal movement.\" Movement disorders were observed in all clinical stages, and could also be a presenting feature, even sans myoclonus. Hyperkinetic movement disorders were more common than hypokinetic movement disorders. An evolution of movement disorders was observed, with ataxia, chorea and dystonia occurring earlier, and parkinsonism later in the disease. Neuroradiological correlates of movement disorders remained unclear.</p><p><strong>Conclusion: </strong>A wide spectrum of movement disorders was observed throughout the clinical stages of SSPE. Most data were derived from case reports and small case series. Multicentric longitudinal studies are required to better delineate the spectrum and evolution of movement disorders in SSPE.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140945657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Brain Stimulation in Patients with Cardiac Implantable Electronic Devices: Pulse Width Pitfalls.","authors":"Jongmok Ha, Dongyeong Lee, Jong Hyeon Ahn, Jin Whan Cho, Jung Il Lee, Alfonso Fasano, Seung Jung Park, Jinyoung Youn","doi":"10.1002/mdc3.14066","DOIUrl":"10.1002/mdc3.14066","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141081528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}